Dongshan Zhang | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. Dongshan Zhang | Drug Discovery and Development | Best Researcher Award

Director at nd Xiangya Hospital | Central South University | China

Prof. Dr. Dongshan Zhang is a highly respected Chief Physician and Professor at Central South University, China. A postdoctoral fellow trained in the United States, he is a PhD supervisor and a recipient of China’s National Top Talent Program for Science and Technology Leaders. As Director of both the Institute of Emergency and Difficult Diseases and the Clinical Medical Research Center for Acute Organ Injury and Repair, he leads cutting-edge medical research. With over 46 SCI publications and multiple patents, his work in acute kidney injury has earned him prestigious awards and international acclaim.

Publication Profile 

Education 

Prof. Zhang pursued rigorous academic training in China and completed his postdoctoral fellowship in the United States, gaining advanced insights into nephrology and translational medicine. He earned his medical and doctoral degrees from top Chinese medical universities, where he laid the foundation for his expertise in acute organ injury. His exposure to international research environments shaped his multidisciplinary approach. Now, as a PhD supervisor, he mentors future scientists and clinicians, promoting global research collaborations and innovation in clinical nephrology and emergency medicine.

Experience 

Prof. Zhang currently serves as Chief Physician and Professor at Central South University, where he is also a Distinguished Shenghua Scholar Professor. He directs two major research institutes: the Institute of Emergency and Difficult Diseases and the Clinical Medical Research Center for Acute Organ Injury and Repair in Hunan Province. Over his career, he has led four NSFC-funded national research projects and served as Associate Editor for top journals. His commercialized patents and extensive publication record reflect his commitment to translational research and clinical excellence.

Awards 

Prof. Zhang’s outstanding contributions have earned him the First Prize of the Natural Science Award of Hunan Province. He has been recognized as a National Top Talent in Science and Technology, awarded for his pioneering work in nephrology and acute organ injury. His research papers have graced the covers of leading journals, affirming his global impact. As a Distinguished Shenghua Scholar Professor and active editorial board member, he continues to shape scientific thought and innovation. His accolades highlight both clinical expertise and trailblazing research excellence.

Research Focus 

Prof. Zhang’s primary research centers on Acute Kidney Injury (AKI), encompassing mechanisms of injury, repair, and translational approaches to therapy. His work explores inflammation, apoptosis, and molecular pathways involved in kidney damage. He leads interdisciplinary teams to develop innovative drug targets and biomarkers, bridging basic science and clinical application. With support from multiple NSFC grants, his lab integrates in vivo models, molecular profiling, and AI-driven analytics to advance precision nephrology. His research contributes to improving prognosis and treatment in critical care settings.

Publication Top Notes

Title: PRDM16 acts as a homeostasis regulation factor to suppress the transition of AKI to CKD via upregulation of eukaryotic initiation factor 6
Journal: Cellular and Molecular Life Sciences
Year: 2025

Title: PRDM16 suppresses pyroptosis to attenuate the progression of AKI caused by rhabdomyolysis via upregulation of USP10
Journal: Cellular and Molecular Life Sciences
Year: 2025

Title: Mmu_circ_0005698/hsa_circ_0085381/miR-532-3p/Arhgdib axis mediates the ischemic progression of acute kidney injury
Journal: International Immunopharmacology
Year: 2025

Title: Recombinant monoclonal antibody siltartoxatug versus plasma-derived human tetanus immunoglobulin for tetanus: a randomized, double-blind, active-controlled, phase 3 trial
Journal: Nature Medicine
Year: 2025

Title: Inhibition of Mettl3 alleviates low-dose cisplatin-induced renal fibrosis and enhances the chemotherapeutic efficacy in mouse models of cancer
Journal: International Journal of Biological Sciences
Year: 2025

Title: PRDM16 suppresses ferroptosis to protect against sepsis-associated acute kidney injury by targeting the NRF2/GPX4 axis
Journal: Redox Biology
Year: 2024

Title: NRF1-induced mmu_circ_0001388/hsa_circ_0029470 confers ferroptosis resistance in ischemic acute kidney injury via the miR-193b-3p/TCF4/GPX4 axis
Journal: Life Sciences
Year: 2024

Title: Discovery and verification of mmu_Circ_26986/hsa_Circ_0072463 as a potential biomarker and intervention target for sepsis-associated acute kidney injury
Journal: Not specified
Year: Not specified

Conclusion

Prof. Dr. Dongshan Zhang is an outstanding candidate for the Research for Best Researcher Award, possessing an exceptional track record in acute organ injury research, prolific publication output, successful grant leadership, and tangible innovations through patents. His blend of academic excellence, clinical relevance, and translational success makes him a model researcher with substantial contributions to global health and kidney disease research. With minor expansion in global collaborations and strategic outreach, his impact can become even more internationally transformative.

Song Guo Zheng | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Song Guo Zheng | Drug Discovery and Development | Best Researcher Award

Chair Professor at Shanghai Jiao Tong University School of Medicine | China

Prof. Song Guo Zheng, M.D., Ph.D., is an internationally renowned immunologist and clinician-scientist specializing in rheumatology, molecular immunology, and translational medicine. He currently serves as Chair Professor and Dean of the School of Cell and Gene Therapy at Shanghai Jiao Tong University. With academic leadership roles across prestigious institutions in the U.S. and China, his pioneering work spans autoimmunity, cell therapy, and immunoregulation. A prolific author with over 110 peer-reviewed publications in top-tier journals, Prof. Zheng is also a highly decorated researcher and active leader in global immunology societies. His contributions continue to shape modern immunotherapy and precision medicine.

Publication Profile 

Google Scholar

Orcid

Education 

Prof. Zheng earned his Ph.D. in Molecular Immunology from the University of Orleans, France (2011), and a Master’s in Pathology and Immunology from Shanghai Medical University (1992). He completed his M.D. at Anhui Medical University (1984). His clinical training included a residency in surgery at Chizhou City Hospital (1984–1989) and an internship at Shanghai Zhabei Hospital (1983–1984). He further pursued a pathology fellowship at Shanghai Medical University Cancer Hospital (1989–1993). These academic and clinical foundations laid the groundwork for a distinguished career in immunology, clinical research, and translational medicine across both China and the United States.

Experience 

Prof. Zheng currently serves as Chair Professor at Shanghai Jiao Tong University and Dean of the School of Cell and Gene Therapy (2023–Present). He previously held senior positions including the Ronald L. Whisler Chair in Rheumatology and Immunology at Ohio State University (2018–2022) and Director at Penn State University’s College of Medicine (2013–2018). His U.S. academic journey began at the University of Southern California as an assistant and associate professor (2004–2013), after postdoctoral work at USC and UCLA. With leadership in research, teaching, and clinical science, he has become a global authority in immunological therapeutics and rheumatology.

Awards

Prof. Zheng has received numerous prestigious honors, including the Outstanding Scientist Award (2023, USA) and the Distinguished Clinical Immunologist Award (2019, China). He was awarded the Edmund L. Dubois Award (2019), NIH STAR Award (2016–2021), and was Chair of NIH MOSS Study Section (2016). Notably, he earned the James R. Klinenberg Award for best immunologist in Southern California (2007) and the Freda Newton Memorial Scholar Award (2006). He is an elected member of The Henry Kunkel Society (2012) and a recipient of the ACR Investigator Award (2008–2010), reflecting his impactful and sustained contributions to clinical immunology.

Research Focus 

Prof. Zheng’s research centers on molecular immunology, particularly in autoimmune diseases, Treg/Th17 cell modulation, and immune tolerance mechanisms. He investigates immunometabolism, gene and cell therapy, and inflammatory signaling pathways with an emphasis on clinical translation. His studies on cytokines, nanomedicine, and immune checkpoint regulation aim to advance precision therapeutics for rheumatic and inflammatory diseases. He integrates cutting-edge techniques including single-cell sequencing, CRISPR-based modulation, and nano-drug delivery systems. His innovative research is highly cited and supports next-generation treatments for autoimmunity, cancer immunotherapy, and organ-specific inflammation, shaping global trends in immune-based medical interventions.

Publication Top Notes

Natural and induced CD4+ CD25+ cells educate CD4+ CD25− cells to develop suppressive activity: the role of IL-2, TGF-β, and IL-10

IL-2 is essential for TGF-β to convert naive CD4+ CD25− cells to CD25+ Foxp3+ regulatory T cells and for expansion of these cells

Role of vitamin A in the immune system

Generation ex vivo of TGF-β-producing regulatory T cells from CD4+ CD25− precursors

Vitamin D and chronic diseases

TGF-β requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+ CD25+ regulatory cells

Natural and TGF-β–induced Foxp3+ CD4+ CD25+ regulatory T cells are not mirror images of each other

Role of TNF–TNF receptor 2 signal in regulatory T cells and its therapeutic implications

Cutting edge: Foxp3+ CD4+ CD25+ regulatory T cells induced by IL-2 and TGF-β are resistant to Th17 conversion by IL-6

Hall of fame among pro-inflammatory cytokines: interleukin-6 gene and its transcriptional regulation mechanisms

The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3

The role of the combination of IL-2 and TGF-β or IL-10 in the generation and function of CD4+ CD25+ and CD8+regulatory T cell subsets

Conclusion

Given his outstanding scientific productivity, leadership in global immunology communities, and groundbreaking research on immune regulation, Prof. Song Guo Zheng is highly suitable for the Best Researcher Award. His body of work demonstrates not only scientific depth and innovation but also sustained impact on the field of immunology and clinical medicine. With ongoing contributions and strategic improvements, he remains a central figure in advancing immune-based therapies and education worldwide.

Cheng Li | Drug Delivery Systems | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Cheng Li | Drug Delivery Systems | Best Researcher Award

Profess at Shanghai Fourth People’s Hospital | School of Medicine | Tongji Universit | China

Prof. Cheng Li  is a distinguished chief physician, professor, and doctoral supervisor in anesthesiology. A visiting scholar at Harvard University , he directs a National Key Clinical Specialty and serves as a leading researcher at the Shanghai Key Laboratory of Anesthesia and Brain Function Regulation . Prof. Li has pioneered 11 innovative technologies enhancing elderly critical care and brain protection . His prolific academic, clinical, and mentorship contributions have earned him national recognition . Dedicated to advancing anesthesia and perioperative science, Prof. Li is shaping the future of surgical medicine through groundbreaking innovation and academic excellence.

Profile 

Scopus

Education

Prof. Cheng Li completed his medical education from top-tier Chinese medical institutions . His rigorous academic training in anesthesiology and perioperative medicine laid the foundation for his specialization in critical care for elderly patients and neurological function regulation . He further enhanced his expertise as a visiting scholar at Harvard University , gaining international exposure and experience. As a committed academician, he continues to mentor postgraduate and doctoral students . Prof. Li’s comprehensive education, both domestic and abroad, has equipped him with deep clinical insight, strong research methodology skills, and a global perspective on patient care .

Experience 

Prof. Li Cheng has over two decades of clinical and research experience in anesthesiology and perioperative medicine . He serves as the Director of a National Key Clinical Specialty and leads a research team at the Shanghai Key Laboratory of Anesthesia and Brain Function Regulation . He is actively involved in hospital technology adoption and has led the development of 11 technologies for elderly and critically ill patients . Prof. Li holds more than 20 academic positions and has supervised 24 postdoctoral, Ph.D., and master’s students . He continues to impact both policy and practice in Chinese medical institutions .

Awards 

Prof. Cheng Li has received numerous prestigious awards recognizing his academic and clinical excellence. These include Shanghai Outstanding Academic Leader, Shanghai Young Top Talent, and the Third Prize of the Shanghai Silver Snake Award. He was named “China’s Good Doctor”, the First Shanghai Good Doctor, and received the Outstanding Young Medical Talent – “Medical Star of Shanghai”. In 2022, he was honored as the “Outstanding Teacher of the Most Beautiful Professional Ethics” by Tongji University. His team has earned collective honors such as the Advanced Collective of the National Health and Wellness System.

Research Focus 

Prof. Li’s research is centered on anesthesia and perioperative management in elderly and critically ill patients. His work on brain protection and neurological regulation has led to 11 innovative clinical technologies. He is actively exploring biomarker-based monitoring, neuro-anesthetic pharmacology, and personalized anesthesia protocols in surgical settings. His involvement in intraoperative brain function control, post-operative cognitive disorder prevention, and advanced anesthesia devices underscores his commitment to translational medicine. Prof. Li’s research integrates clinical expertise with cutting-edge science to elevate surgical safety and efficiency, especially for high-risk elderly patients.

Publication Top Notes

Title: Three-stage sequential targeted nasal drops for correcting abnormal mitochondrial division in microglia
Journal: Bioactive Materials
Year: 2025

Title: Lactate inhibits T-cell activation in sepsis through CD40LG downregulation and SOCS3-mediated JAK1/STAT3 pathway suppression
Journal: Biochimica et Biophysica Acta – Molecular Basis of Disease
Year: 2025

Title: Clinical biomarkers of perioperative neurocognitive disorder: initiation and recommendation
Journal: [Journal name not specified]
Year: 2025
Cited by: 1

Title: Thermo-responsive and biodegradable MoS2-based nanoplatform for tumor therapy and postoperative wound management
Journal: Journal of Colloid and Interface Science
Year: 2025
Cited by: 2

Title: Disrupting the activity of endogenous gas neurotransmitters: a therapeutic strategy using engineered metal–organic frameworks for cancer
Journal: Medical Gas Research
Year: 2025

Conclusion

In conclusion, Prof. Cheng Li’s impactful innovations, prolific research output, and exceptional leadership in anesthesiology make him a highly deserving candidate for the Best Researcher Award. His clinical and academic contributions have significantly advanced patient care and scientific knowledge in anesthesiology, earning national recognition and academic prestige. With ongoing focus and minor enhancements in international outreach and interdisciplinary integration, he stands poised to further shape the global landscape of perioperative and critical care research.

Wai Har Ng | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Ms. Wai Har Ng | Drug Discovery and Development | Best Researcher Award

Senior Research Associate at National Cancer Centre Singapore | Singapore

Ms. Wai Har Ng is a Senior Research Associate at the National Cancer Centre Singapore with over two decades of experience in cancer biology and translational research. His scientific journey spans genetic engineering, molecular oncology, and personalized therapeutics, with a strong focus on hepatocellular carcinoma, peritoneal carcinomatosis, and colorectal cancer. A dynamic contributor to national research consortiums, Ng WH has authored numerous high-impact publications and excels in molecular, cellular, and in vivo experimental platforms. Known for his collaborative spirit, he plays a pivotal role in mentoring, protocol development, and driving clinical translation in cancer therapy through precision medicine and molecular marker discovery.

Publication Profile 

Scopus

Education

Ms. Wai Har Ng obtained a Master of Science in Genetic Engineering from University Putra Malaysia (2005), where his dissertation focused on gene expression profiling of oil palm root systems using EST and microarray technology. He earned his Bachelor of Science in Biotechnology (2000) from the same university, working on Arabidopsis root transformation. His foundational education was completed at Chong Hwa Independent High School, Kuala Lumpur, from 1990–2000, with certifications including STPM, SPM, and SRP. His early academic training at SRJK (C) Tsun Jin laid the groundwork for a career defined by scientific curiosity, discipline, and innovation in molecular biosciences.

Experience 

Ms. Wai Har Ng currently serves as a Senior Research Associate at the National Cancer Centre Singapore (2017–present), where he spearheads research on molecular therapeutics and biomarker discovery. He previously worked as a Research Officer and Research Associate at the same institute (2004–2017), contributing to groundbreaking oncology studies. Earlier, he served at the Malaysian Agricultural Research & Development Institute (MARDI) from 2003–2004. His academic skillset spans molecular biology, proteomics, imaging, animal studies, and lab management. Proficient in BSL2 safety, grant collaboration, and multidisciplinary research, he plays a key role in mentoring, lab operations, and translational biomedical research.

Awards 

While specific awards were not listed, Ng WH’s achievements are evident through his prolific publication record in high-impact journals, participation in national research consortia like the Singapore Peritoneal Oncology Study (SPOS) and Singapore Gastric Cancer Consortium (SGCC), and recognition as a core contributor to precision oncology research. His co-authorship on influential studies in Scientific Reports, Cell Reports Medicine, and International Journal of Molecular Sciences demonstrates academic recognition and leadership. His technical versatility and mentorship roles further highlight his contribution to national cancer research excellence. If formal awards were earned, these would further bolster his already commendable profile.

Research Focus 

Ng WH focuses on translational cancer research with emphasis on hepatocellular carcinoma, colorectal cancer, peritoneal carcinomatosis, and liposarcoma. His work integrates drug synergy, molecular profiling, biomarker discovery, and machine learning to optimize personalized cancer therapies. He is proficient in CRISPR, ddPCR, organoid modeling, xenografts, and immunofluorescence microscopy. A key area includes developing predictive molecular signatures for chemotherapy response and leveraging advanced imaging to study tumor behavior. With over 13 peer-reviewed publications, Ng WH bridges basic science and clinical application, contributing to a future where cancer treatment is personalized, precise, and highly effective.

Publication Top Notes

Title: Vinorelbine Improves the Efficacy of Sorafenib against Hepatocellular Carcinoma: A Promising Therapeutic Approach
Journal: International Journal of Molecular Sciences
Year: 2024
Citations: 5

Title: Everolimus Acts in Synergy with Vinorelbine to Suppress the Growth of Hepatocellular Carcinoma
Journal: International Journal of Molecular Sciences
Year: 2024
Citations: 4

Conclusion

Ms. Wai Har Ng is a highly competent and experienced researcher whose scientific contributions have advanced the field of cancer biology and therapeutics. Her technical mastery, consistent publication output, and collaborative involvement with national research consortia highlight her as a valuable asset to the research community. With increased visibility through leadership roles in publications and funding acquisition, she would stand out even more prominently. She is a strong and deserving candidate for the Best Researcher Award, given her sustained excellence, innovation, and impact in translational cancer research.

Teodora-Eliana Petcov | Drug Delivery Systems | Best Researcher Award

Published on by Top Pharmaceutical

Ms. Teodora-Eliana Petcov | Drug Delivery Systems | Best Researcher Award

Teodora-Eliana Petcov at National University of Science and Technology POLITEHNICA Bucharest | Romania

Teodora Eliana Petcov is a driven biomedical researcher with a strong foundation in biomaterials, molecular biology, and nanotechnology. Passionate about innovation in drug delivery and regenerative medicine, she has already co-authored scientific publications in reputed journals. Her international internships, multidisciplinary skills, and involvement in EU-funded research projects underscore her commitment to advancing medical technologies. Teodora balances research excellence with volunteer leadership, contributing to both academic and community-driven initiatives. With a sharp analytical mind, hands-on lab experience, and cross-cultural exposure, she exemplifies the next generation of biomedical scientists focused on improving patient care through science and innovation.

Publication Profile 

Scopus

Education

Teodora holds a Bachelor’s degree in Medical Engineering from the Polytechnic University of Bucharest  with a focus on biomaterials and medical devices. She is currently pursuing her Master’s in Biocompatible Substances, Materials, and Systems at the National University of Science and Technology POLITEHNICA Bucharest. Her thesis explored the internalization of nano-sized devices in biological structures. She was a visiting student at “Horia Hulubei” Nuclear Institute and Floreasca Emergency Hospital. Her academic path is complemented by certifications in English  and psycho-pedagogical training, showcasing both technical expertise and educational versatility.

Experience 

Teodora has completed multiple research internships, including roles in molecular biology and materials science labs. She gained practical expertise in 3D bioprinting, SEM techniques, SolidWorks, and conducted advanced testing like DSC and DMA. She has contributed to projects at the National Institute of Physics and Nuclear Engineering, University of Campania in Italy, and worked on PNRR-funded research on bone regeneration and multiple myeloma. Additionally, she has volunteered extensively in cultural and scientific event organization, holding assistant coordinator roles in Zenezia and MED, where she honed human resources, leadership, and scientific communication skills.

Awards  

Teodora has been recognized for her academic excellence and community involvement from high school through higher education. She received top honors for her Bachelor’s thesis, was selected for the prestigious ROSE program, and presented at the “Info-Practic” National Symposium on artificial intelligence. She participated in EU-supported initiatives like ERASMUS+ “Be a Buddy, Not a Bully” and contributed to major national projects, including the ongoing PNRR-funded research on personalized bone regeneration. Her work on cutting-edge nanostructures and her leadership in volunteer networks demonstrate her well-rounded excellence and dedication to scientific and societal progress.

Research Focus 

Teodora focuses on biomedical applications of nanotechnology, with a keen interest in targeted drug delivery, biopolymeric material synthesis, and regenerative medicine. Her Master’s research and publications revolve around understanding how nanostructures interact with cellular systems to improve treatment precision in diseases like multiple myeloma. She also explores the use of 3D printed biomaterials and advanced materials characterization techniques (SEM, DSC, DMA). Her interdisciplinary research combines materials science, molecular biology, and bioengineering to design patient-specific, low-toxicity solutions, positioning her at the frontier of precision and personalized medicine.

Publication Top Notes

Title: Nanostructures: An Efficient Drug Delivery Platform for Therapy of Multiple Myeloma
Year: 2025

Conclusion

Teodora Eliana Petcov is a highly promising emerging researcher whose interdisciplinary approach, early scientific contributions, and strong practical expertise align closely with the vision of the Best Researcher Award. Her dedication to innovation in biomaterials, nanotechnology, and regenerative medicine showcases both depth and futuristic relevance.

Miao Zhou | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Miao Zhou | Precision Medicine | Best Researcher Award

Prof. Miao Zhou at Guangdong Provincial People’s Hospital, China.

Dr. Miao Zhou is a distinguished oral and maxillofacial specialist, currently serving as Chief Physician and Associate Director at the Stomatology Department of Guangdong Provincial People’s Hospital. He is also a supervisor of postgraduate and postdoctoral researchers. An innovator in oral regenerative medicine, he founded the 3D Bioprinting and Regenerative Medicine Branch of the Guangdong Society of Biomedical Engineering. His pioneering research bridges clinical practice and cutting-edge biotechnology, advancing solutions for complex craniofacial conditions. With deep expertise in biomaterials, stem cells, and exosomes, Dr. Zhou continues to drive impactful research and medical education in the fields of maxillofacial rehabilitation and tissue engineering.

Publication Profile 

Scopus

Education

Dr. Miao Zhou earned his Ph.D. in 2009 from Peking University, one of China’s top-tier institutions, where he focused on maxillofacial rehabilitation using functional biomaterials and tissue engineering. His doctoral thesis explored clinical solutions for oral and maxillofacial defects through bio-integrative materials and scaffold systems. This strong academic foundation laid the groundwork for his later interdisciplinary innovations in regenerative medicine. In addition to his formal education, Dr. Zhou has participated in numerous continuing education programs and scientific collaborations, refining his expertise in 3D printing, stem cell therapy, and implantology, and training the next generation of specialists in advanced dental medicine.

Experience

With over 15 years of clinical and research experience, Dr. Miao Zhou is a Chief Physician and Associate Director at Guangdong Provincial People’s Hospital’s Stomatology Department. He supervises both postgraduates and postdocs, guiding translational research in tissue regeneration. He has served as Principal Investigator on numerous national and provincial-level projects, especially in the application of 3D-printed biomimetic scaffolds and exosomes. As a research leader, Dr. Zhou has pioneered innovations in craniomaxillofacial bone regeneration and soft tissue reconstruction. His clinical expertise, combined with academic leadership, positions him as a key influencer in oral regenerative therapy and personalized medical biomaterial development.

Awards 

Dr. Zhou has received numerous accolades, including the First Prize for Excellent Paper at the 6th China International & 9th China Academic Conference of Oral and Maxillofacial Surgery. His recognition reflects significant contributions to clinical and translational research. He has been honored by national bodies such as the National Natural Science Foundation of China and the Guangzhou Healthcare Innovation Program for his leadership in 3D bioprinting and regenerative medicine. As the founder of the 3D Bioprinting and Regenerative Medicine Branch under the Guangdong Society of Biomedical Engineering, his efforts have helped shape emerging medical frontiers and drive collaborative innovation.

Research Focus 

Dr. Zhou’s research centers on 3D-printed biomimetic scaffolds, stem cell therapy, and exosome-based interventions for oral and maxillofacial regeneration. His work explores how engineered tissues and cell-based therapies can reconstruct large jaw defects, restore bone function, and integrate with host tissues. His studies focus on osteoinduction, vascularization, and personalized medicine approaches using biocompatible materials. By leveraging cutting-edge printing technologies and biomolecular signaling pathways, Dr. Zhou aims to bridge gaps between laboratory research and clinical application—delivering impactful solutions for tissue repair and oral implantology. His interdisciplinary approach integrates biomaterials science, dentistry, and regenerative medicine to redefine patient care.

Publication Top Notes

  • An engineered M2 macrophage-derived exosomes-loaded electrospun biomimetic periosteum promotes cell recruitment, immunoregulation, and angiogenesis in bone regeneration
  • Osteogenically committed hUCMSCs-derived exosomes promote the recovery of critical-sized bone defects with enhanced osteogenic properties
  • 3WJ RNA Nanoparticles-Aptamer Functionalized Exosomes From M2 MacrophagesTarget BMSCs to Promote the Healing of Bone Fractures

E Marimuthu | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. E. Marimuthu | Drug Discovery and Development | Best Researcher Award

Professor at Arunachal University of Studies | Ayya Nadar Janaki Ammal College | Madurai Kamaraj University | India

Dr. E. Marimuthu is a dedicated researcher and academician specializing in plant biotechnology, microbiology, and molecular biology. With over 15 years of experience in research and education, he has made significant contributions through patents, microbial sequencing, and ethnobotanical surveys. His work focuses on endangered species conservation, natural IAA production, and nanomedicine applications for cancer. Dr. Marimuthu currently serves as a Professor at Arunachal University of Studies. His multidisciplinary efforts bridge traditional knowledge with modern scientific innovations, making him a standout figure in applied life sciences and pharmaceutical biotechnology.

Publication Profile 

Scopus 

Education

Dr. Marimuthu earned his Ph.D. from Madurai Kamaraj University in 2017, focusing on the in vitro conservation of endangered tree species in the Southern Western Ghats . He completed his M.Phil. and M.Sc. from Ayya Nadar Janaki Ammal College, conducting ethnomedicinal surveys and plant growth hormone studies. His academic foundation began with a B.Sc. in Botany. Each academic milestone has been rooted in biodiversity conservation and plant-microbe interactions, establishing a strong base for his later patents and microbial gene discoveries .

Experience

Dr. Marimuthu has held various academic and research roles: Professor and Associate Professor at Arunachal University of Studies (2023–present), Assistant Professor at Sri Vidya Mandir and Vivekanandha Colleges, and Associate Scientist at Aakash Green Research Pvt. Ltd. Earlier, he served as a JRF at TBGRI, Kerala  and Technical Assistant at Kalasalingam University. His experience spans plant tissue culture, cell line work, and microbial molecular studies. With deep involvement in both lab and field research, he has nurtured innovations from concept to patent, while also mentoring students and contributing to curriculum development.

Awards 

Dr. E. Marimuthu is a prolific innovator with 8 Indian patents and 2 Canadian patents, showcasing breakthroughs in nanomedicine, cancer immunotherapy, and plant-based biotechnology . His bacterial gene sequences are submitted to NCBI, emphasizing novel microbial discoveries from unique ecological niches. Recognized nationally and internationally for his translational research, he has pioneered techniques that merge traditional plant knowledge with high-end scientific platforms. Though specific named awards are not listed, his patent record and academic promotions signify a distinguished and respected trajectory in bioscience innovation and interdisciplinary research.

Research Focus 

Dr. Marimuthu’s research emphasizes plant tissue culture, natural growth hormone production, ethnomedicinal conservation, and nanotechnology-enhanced drug delivery . He explores molecular markers for documenting genetic diversity and has successfully isolated bacterial strains producing Indole-3-acetic acid (IAA) to promote plant growth . He integrates ethnobotanical knowledge with biotechnological advancements to develop eco-friendly, scalable solutions for agriculture and medicine. His cutting-edge work in cancer-targeting mesenchymal stem cell therapy, as well as nano-immunotherapy, reflects a visionary outlook on the future of personalized medicine and sustainable pharmacology.

Publication Top Notes

Title: Chemical profiling and in silico molecular docking studies of phytochemicals from Hydnocarpus macrocarpa Warb: A GC–MS, FTIR, and physico-chemical analysis
Journal: Journal of Molecular Structure
Year: 2025

Conclusion

Dr. E. Marimuthu is an outstanding candidate for the Best Researcher Award, showcasing a rare combination of field knowledge, lab precision, patent-oriented innovation, and a commitment to both fundamental and applied science. His work contributes significantly to biotechnology, pharmacology, environmental microbiology, and regenerative agriculture.

Meixian Zhang | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Meixian Zhang | Clinical Trials | Best Researcher Award

Director at Taizhou Hospital of Zhejiang Province | China

Dr. Meixian Zhang is an Associate Researcher and Master’s Supervisor at Wenzhou Medical University. With a Ph.D. in Public Health, she specializes in clinical epidemiology, evidence-based medicine, and obesity research. Her career is marked by over 35 SCI journal publications and leadership in multiple national and provincial research projects. She is deeply committed to tackling childhood obesity through genetic and dietary studies. With a passion for translational health research and mentoring, Dr. Zhang has earned recognition through innovation, impactful findings, and dedicated academic service. She continues to push boundaries in the fight against obesity-related health risks.

Publication Profile 

Orcid

Education

Dr. Zhang Meixian earned her Ph.D. in Public Health, specializing in childhood obesity and molecular epidemiology. Her academic journey began with a strong foundation in clinical medicine and public health, followed by doctoral research focusing on genetic predisposition to pediatric adiposity. She has been trained extensively in clinical epidemiology, biostatistics, and molecular genetics. Her postgraduate training enabled her to explore multifaceted aspects of obesity-related metabolic disorders and the implementation of evidence-based interventions. The academic rigor and scientific integrity developed during her education continue to guide her ongoing contributions to translational research and public health education.

Experience

With over a decade of research and academic experience, Dr. Zhang currently serves as an Associate Researcher at Wenzhou Medical University. She has supervised graduate students and led numerous scientific projects as principal investigator. Her work bridges molecular epidemiology, public health policy, and clinical research. She’s received major grants from the National Natural Science Youth Fund and Zhejiang provincial programs. She has also contributed to high-impact studies on obesity, SNPs, and weight management. Through editorial appointments and cross-institution collaborations, she continues to expand the reach of her research across China and the global scientific community.

Awards 

Dr. Zhang has received significant recognition for her contributions to medical research. She has been awarded grants from the National Natural Science Youth Fund and the Basic Public Welfare Research Program of Zhejiang Province as a Principal Investigator. Additionally, she has secured two provincial-level medical and science grants and one from the Taizhou Science and Technology Council. Her innovative research has led to two authorized national invention patents and one software copyright. These accolades underscore her scientific excellence and translational impact in obesity and metabolic health, positioning her as a leading figure in evidence-based public health research.

Research Focus 

Dr. Zhang’s research centers on childhood obesity, metabolic syndrome, and genetic susceptibility markers. She investigates the role of leptin, adiponectin, FTO gene variants, and other biomarkers in the development of obesity. Her work bridges molecular epidemiology with clinical nutrition, validating interventions such as intermittent fasting, calorie restriction, and meal replacements. Additionally, she explores single-nucleotide polymorphisms (SNPs) and their regulatory functions in metabolic pathways. Dr. Zhang’s interdisciplinary approach integrates public health, genomics, and preventive medicine, aiming to deliver targeted health strategies for pediatric populations in China and globally.

Top Publications

Title: Willingness of Older Adults with Chronic Diseases to Receive a Booster Dose of Inactivated Coronavirus Disease 2019 Vaccine: A Cross-Sectional Study in Taizhou
Year: 2025

Conclusion

Dr. Zhang Meixian’s academic rigor, originality, and focused contributions in combating obesity through evidence-based and genetics-informed approaches position her as an outstanding candidate for the Best Researcher Award. Her ability to translate complex research into meaningful public health solutions, combined with her strong record of funding, publications, and innovation, make her a worthy and impactful recipient of this recognition. With minor strategic advancements, her global influence is poised to grow even further.

Rulla Tamimi | Immunotherapy | Best Researcher Award

Published on by Top Pharmaceutical

Rulla Tamimi | Immunotherapy | Best Researcher Award

Dr. Rulla Tamimi at Weill Cornell Medicine Dept of Healthcar, United States.

Dr. Rulla M. Tamimi is a leading cancer epidemiologist and Professor of Population Health Sciences and Pathology at Weill Cornell Medicine. With over two decades of experience in breast cancer research, her work centers on cancer risk prediction, environmental exposures, and molecular epidemiology. A pioneer in integrating biomarkers and epidemiologic data, she has advanced understanding of breast cancer heterogeneity and disparities. Dr. Tamimi is also a principal investigator for multiple NIH-funded studies and a dedicated educator. She plays a critical role in shaping future public health strategies and improving women’s health through rigorous research and community-engaged science.

Publication Profile 

Scopus

Education

Dr. Tamimi holds a B.S. in Biology from Tufts University (1993), followed by an M.S. (1999) and Sc.D. (2003) in Epidemiology from the Harvard T.H. Chan School of Public Health. Her academic training is rooted in public health, statistical methods, and cancer epidemiology. She received advanced training at Harvard, which set the stage for a prolific research and academic career in molecular and clinical epidemiology. Her education enabled her to translate complex biological mechanisms into population-level cancer prevention strategies, and her leadership has consistently bridged rigorous epidemiological research with patient-focused public health innovation.

Experience

Dr. Tamimi has held prestigious academic positions including Instructor, Assistant Professor, Associate Professor at Harvard Medical School and Harvard T.H. Chan School of Public Health (2003–2020). She currently serves as Professor at Weill Cornell Medicine (2020–Present). With over 20 years in academic medicine, she’s also served as Associate Epidemiologist at Brigham and Women’s Hospital. Dr. Tamimi leads NIH- and NCI-funded multi-institutional projects, mentoring future epidemiologists while advancing cancer research. She has contributed to global education through lectures and program direction across institutions including Boston University, Harvard, and National University of Singapore.

Awards 

Dr. Tamimi has received multiple accolades for her visionary research. She earned the “Good Questions Meet Big Data” Ideation Challenge Award from Harvard Catalyst in 2017 and became a Susan G. Komen Scholar in 2020. Her election to prominent organizations such as the American Association for Cancer Research, Society for Epidemiologic Research, and Cornell Center for Health Equity highlights her influence in the field. These recognitions reflect her leadership in molecular epidemiology, commitment to health equity, and significant contributions to cancer prevention research on both national and global scales.

Research Focus 

Dr. Tamimi’s research explores breast cancer heterogeneity, environmental exposures, and the biological underpinnings of cancer risk. Her projects evaluate how dietary carotenoids, genetic variants, circulating metabolites, and breast tissue markers influence cancer outcomes. She is especially interested in aggressive tumor subtypes, breast cancer in young women, and disparities across racial and socioeconomic lines. Current studies also examine stromal contributions to carcinogenesis and social determinants of health through the SoCa Center. Her work connects molecular biology with epidemiological insights to improve early detection, prevention, and personalized treatment strategies for breast cancer.

Publication Top Notes

  • Regular aspirin use, breast tumor characteristics and long-term breast cancer survival
  • Development and validation of a risk prediction model for premenopausal breast cancer in 19 cohorts
  • Disparities in adherence to guideline-concordant care and receipt of immunotherapy for Non-Small cell lung cancer in the United States
  • Thromboembolic Events Are Increased After Splenectomy in Postmenopausal Women
  • The Breast Tumor Immune Microenvironment of DNA Double-Strand Break Repair Pathogenic Variant Carriers Is Enriched with Tumor-Associated Macrophages
  • The impact of reproductive factors on breast tumor and normal-adjacent tissue immune profile from menarche to menopause
  • Associations of alcohol consumption with expression of CD44, CD24, and ALDH1A1 stem cell markers in benign breast biopsy samples
  • Breast cancer prevention by short-term inhibition of TGFβ signaling
  • Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses’ health study
  • A genome-wide association study of mammographic texture variation